港股异动丨华为概念股走强 Mate30系列手机明日发布 料下半年出货2000万部
格隆汇9月18日丨华为概念股走强,其中瑞声科技(2018.HK)暴涨近10%,丘钛科技(1478.HK)和比亚迪电子(0285.HK)大涨约7%。

从华为终端有限公司获悉,北京时间9月19日20时,华为将在德国慕尼黑发布Mate30系列旗舰手机。天风国际分析师郭明錤9月17日晚间发布报告指出,华为高端手机约70%是在中国销售,故因欠缺GMS预装而无法在海外市场销售对Mate30出货影响有限,预估2019年下半年Mate30系列出货量约2000万部。而这样的出货量也将远远超过他们的预期。华为、三星和苹果对于多镜头的青睐,也直接刺激了相关产业的发展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.